Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Research article

Bone events and evolution of biologic markers in Gaucher disease before and during treatment

Jérôme Stirnemann12*, Nadia Belmatoug3, Corine Vincent2, Olivier Fain1, Bruno Fantin3 and France Mentré2

Author Affiliations

1 Médecine Interne, Hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, Université Paris XIII, Referral Center for Lysosomal Diseases (RCLD), Avenue du 14 juillet, 93140 Bondy Cedex, France

2 INSERM, UMR 738, Université Paris-Diderot, Hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris Cedex 18, France

3 Médecine Interne, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris VII, Referral Center for Lysosomal Diseases (RCLD), 100, boulevard du Général Leclerc, 92110 Clichy Cedex, France

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:R156  doi:10.1186/ar3111

Published: 9 August 2010

Abstract

Introduction

Known biomarkers of Gaucher-disease activity are platelets, chitotriosidase, angiotensin-converting enzyme (ACE), tartrate-resistant acid phosphatase (TRAP) and ferritin. The aim of this study was to retrospectively evaluate the frequency of bone events (BE) and biomarker changes during two periods: diagnosis to first enzyme-replacement therapy (ERT) and the latter to the closing date.

Methods

BE of 62 treated patients, among the 73-patient cohort followed at Beaujon Hospital, Clichy, France, were described with Kaplan-Meier curves, and linear-mixed models were used to analyze their biomarker changes and the influence of several covariates (splenectomy, diagnosis year, genotype, age at diagnosis and sex).

Results

BE occurred before (54 events in 21 patients), but also during, ERT (12 events in 10 patients), with respective frequencies (95% confidence interval) at 10 years of 22.4% (13.3 to 36.3) and 20.0% (10.2 to 36.9). Biomarker slope changes before and during ERT differed significantly for platelets (+190/mm3/year and 7,035/mm3/year, respectively; P < 0.0001) and ferritin (+4% and -14%; P < 0.0001). High ferritin levels and low platelet counts at ERT onset were significantly associated with BE during ERT (P = 0.019 and 0.039, respectively). Covariates significantly influenced biomarker changes (baseline and/or slope): splenectomy affected platelets (baseline and changes), TRAP changes and chitotriosidase changes; diagnosis date influenced ACE and TRAP baseline values; and genotype influenced chitotriosidase baseline and changes.

Conclusions

Platelet counts and ferritin levels and their slope changes at ERT onset seem to predict BE during treatment. Biomarker baseline values and changes are dependent on several covariables.